Compare Merck & Co., Inc. (MRK) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: Merck & Co., Inc. is far larger — about 50× ABRDN Physical Gold Shares ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| MRK | SGOL | |
|---|---|---|
Market Cap | $351.28B | $7.03B |
Volume | 7,969,665 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $156.43 | $51.41 |
52-Week Low | $82.49 | $37.54 |
Typical Hold Time | 98 Days | 57 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
SGOL trades at $39.92, up 2.31% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks key financial ratio data, making fundamental assessment difficult. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices under pressure from rising rates but finding some support from softer inflation data.
The outlook remains cautious due to bearish technicals and macroeconomic headwinds from interest rates. Investment opportunity hinges on gold's safe-haven appeal if economic uncertainty rises, but risks include persistent rate hikes and dollar strength dampening gold demand. Without current fundamentals, valuation is unclear.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
